Alistair Smith

IAM Research

The Patent 1000 focuses exclusively on patent practice and has firmly established itself as the definitive 'go-to' resource for those seeking world-class legal patent expertise.

Recommended - Individuals: prosecution

For the past 140-odd years, Davies Collison Cave has maintained its “burnished reputation as a top-notch Australian firm in the biotech space”. Sitting comfortably on top of the prosecution table, the 50-strong IP outfit consistently files among the highest number of originating patent applications across all technical disciplines. The superb technical proficiency of its patent attorneys has enticed a raft of household names, including Novartis, Gilead, ITW, Microsoft, CSL, Telstra and CSIRO, to hand over their invaluable patent portfolios. It surprises no one that the patent powerhouse has earned rave reviews: “DCC are a pleasure to work with. They are happy to work to our timelines and are always able to meet very tight turnaround times and deadlines when it is requested of them.” “They are extremely knowledgeable, not only on matters relating to IP law, but also the science involved, and take the time to understand the products we are developing and therapeutic areas we are targeting.” Leading the charge is patent group manager David Webber, who is equally adroit at drafting patents as he is in providing infringement briefs and freedom-to-operate advice. Physics doctorate holder Hannah Brown advises on a wide range of technologies, including information and communications technology, microelectronics and physics. An electrical engineer by trade, Ross Clark takes a special interest in green technology and is always passionate about devising the optimal IP strategies for his clientele. A guiding light in intellectual property, the organic chemistry and pharmaceutical group leader Michael Caine currently serves as president of the Institute of Patent and Trademark Attorneys of Australia, where he has been a member since 2001. Patent attorneys Alistair Smith, Gavin Recchia and Alex Tzanidis make their debut in the IAM Patent 1000 this year. Cambridge graduate Smith draws judiciously on his UK and Europe drafting experience and now heads up the medical devices practice. Biology specialist Recchia has unrivalled expertise in matters relating to devices for use in medical treatment, diagnostics and molecular biology research, and lectures widely on biotechnology patenting issues. Biotechnology maven Tzanidis receives effusive praise from one of his clients: “Alex has been instrumental in ensuring that we had adequate protections for our IP, particularly in the early stages of development. He is highly knowledgeable and such a pleasure to work with.” Meanwhile, Paul Dewar, Ian Pascarl and Chris Jordan anchor the IP dispute team with aplomb. Dewar has particular expertise in relation to pharmaceutical patent litigation and has a detailed understanding of the operation of the Australian Register of Therapeutic Goods and Pharmaceutical Benefits Scheme. IP all-rounder Pascarl has a proven track record of success in numerous IP disputes throughout his career. Last but not least, Jordan has made frequent appearances before all levels of the Australian courts in a number of significant IP litigation matters.

Unlock unlimited access to all IAM content